Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs ELESTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Estradiol is a hormone that binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, leading to effects such as endometrial growth, breast development, and regulation of the menstrual cycle. It also has non-genomic actions via membrane-associated estrogen receptors.
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis,Off-label: Treatment of menopausal depression, urogenital atrophy
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Apply 1.25 g (2 actuations) of 0.06% gel to upper arm/shoulder once daily; may adjust based on response.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Terminal elimination half-life of estradiol is approximately 13-16 hours. Steady-state concentrations are achieved after 2-4 days of daily application. Clinical context: The half-life supports once-daily dosing for transdermal delivery.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation. Metabolites include estrone and estriol, which are conjugated with sulfate or glucuronide and excreted in urine.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Estradiol (active metabolite of estradiol hemihydrate) is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 60-80%), with about 10% excreted in feces via bile. Unchanged estradiol excretion is minimal.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Estradiol is 97.5-99% bound to plasma proteins, primarily albumin (60-70%) and sex hormone-binding globulin (SHBG, 30-40%).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Volume of distribution of estradiol is approximately 1.2 L/kg (range 0.9-1.5 L/kg). This high Vd indicates extensive tissue distribution and binding, including to estrogen receptors in target organs.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Transdermal gel: Bioavailability is approximately 3-5% compared to intravenous administration due to skin metabolism and retention. The absolute bioavailability via the transdermal route is 82% relative to a reference transdermal delivery system. Oral estradiol has low bioavailability (5-10%) due to first-pass metabolism.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
No specific dose adjustment provided; use with caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Contraindicated in severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Use with caution; consider lower starting dose due to increased risk of adverse effects.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of endometrial cancer, breast cancer, stroke, and pulmonary embolism have been reported. Use with progestin in women with an intact uterus reduces risk of endometrial hyperplasia/carcinoma.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Risk of endometrial cancer: Use adequate progestin in women with an intact uterus,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, MI, especially in smokers and women with hypertension,Breast cancer: Increased risk with prolonged use, especially with combination therapy,Dementia: Increased risk in women over 65,Gallbladder disease: Increased risk,Hypertriglyceridemia: May occur, caution in patients with elevated triglycerides,Hepatic impairment: Use caution, monitor liver function,Hypothyroidism: May increase thyroid-binding globulin, adjust thyroid replacement,Fluid retention: Use caution in conditions affected by edema,Hypocalcemia: Use caution in patients with hypoparathyroidism,Ovarian cancer: Possibly increased risk with estrogen-alone use,Exacerbation of endometriosis,Hereditary angioedema: May exacerbate,Porphyria: May exacerbate
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active DVT, PE, or history of these conditions,Active or recent arterial thromboembolic disease (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hepatic impairment or disease,Known or suspected pregnancy,Hypersensitivity to estradiol or any component of the product
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
Grapefruit and grapefruit juice may increase estradiol systemic exposure and should be avoided during treatment. No other significant food interactions are known.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Estrogens are not recommended during pregnancy. First trimester: increased risk of congenital anomalies (e.g., cardiovascular defects, limb reduction). Second/third trimester: fetal harm including vaginal adenosis, cervical erosion, and possible transplacental carcinogenesis. Use is contraindicated in pregnancy.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Estradiol is excreted in breast milk in small amounts. The milk-to-plasma ratio is estimated at 0.2-0.4. Limited data suggest no adverse effects in nursing infants at typical doses, but caution is advised due to potential for reduced milk production. Use only if clearly needed.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment studies exist due to contraindication.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
ELESTRIN (estradiol vaginal gel) is a bioidentical estradiol formulation for moderate-to-severe dyspareunia due to vulvar and vaginal atrophy. Apply exactly at the applicator mark; overapplication does not increase efficacy but raises systemic absorption. Use the lowest effective dose for the shortest duration. Contraindicated in undiagnosed vaginal bleeding, breast cancer (known/suspected), or estrogen-dependent neoplasia.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
Apply the gel at the same time each day, using the provided applicator to the exact fill line.,Do not use more than prescribed; more gel does not improve symptoms and increases systemic estrogen exposure.,Wash hands immediately after application; avoid contact with others (especially men, children, pets) until the gel dries.,Report any unexpected vaginal bleeding, breast lumps, or signs of thromboembolism (chest pain, leg swelling, sudden headache) to your healthcare provider.,If you are a smoker over 35, you have an increased risk of serious cardiovascular side effects; discuss smoking cessation with your doctor.,Do not use vaginal lubricants or other products within 30 minutes before or after applying ELESTRIN, as they may interfere with absorption.
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs ELESTRIN, answered by our medical review team.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. ELESTRIN is a Estrogen Replacement Therapy that works by Estradiol is a hormone that binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, leading to effects such as endometrial growth, breast development, and regulation of the menstrual cycle. It also has non-genomic actions via membrane-associated estrogen receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and ELESTRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of ELESTRIN is: Apply 1.25 g (2 actuations) of 0.06% gel to upper arm/shoulder once daily; may adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and ELESTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. ELESTRIN is classified as Category C. Estrogens are not recommended during pregnancy. First trimester: increased risk of congenital anomalies (e.g., cardiovascular defects, limb reduction). Second/third trimester: feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.